Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 12/20 | 0.66 |
| ▸ | FAAH | O00519 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 5/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MET | P08581 | 1/20 | 0.52 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.51 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4731619 | 0.80 | MAOB (1.00) | MAOBFAAHNPC1RAB9AMAOA | |
| SCHEMBL5905673 | 0.79 | MAOB (0.62) | MAOBNPC1RAB9AMAOASMN1; SMN2 | |
| SCHEMBL9220021 | 0.78 | MAOB (0.78) | MAOBNPC1RAB9APKMMAOA | |
| SCHEMBL31123683 | 0.77 | MAOB (0.63) | MAOBNPC1RAB9APKMMAOA | |
| SCHEMBL1697225 | 0.77 | MAOB (0.68) | MAOBNPC1RAB9APKMMAOA | |
| SCHEMBL31123661 | 0.75 | MAOB (0.53) | MAOBNPC1RAB9APKMMAOA | |
| SCHEMBL9217059 | 0.75 | MAOB (0.60) | MAOBNPC1RAB9AMAOAPARP15 | |
| SCHEMBL9217058 | 0.75 | MAOB (0.60) | MAOBNPC1RAB9AMAOAPARP15 | |
| SCHEMBL107322 | 0.75 | MAOB (0.83) | MAOBNPC1RAB9AMAOA | |
| SCHEMBL8672485 | 0.74 | MAOB (1.00) | MAOBNPC1RAB9AMAOASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1996001107-A1 | USE OF PHARMACEUTICAL AGENTS FOR RESTORING, ALLEVIATION, OR TREATMENT OF IMMUNODEFICIENCY, INCLUDING THE ALLEVIATION OR TREATMENT OF THE IMMUNE DYSFUNCTION RELATED TO INFECTION WITH HUMAN IMMUNODEFICIENCY VIRUSES (HIV) OR RELATED VIRUSES | HOFMANN BO ARNE (DK) | 1996-01-18 | — | — | WO | disclosed |